<DOC>
	<DOCNO>NCT01273103</DOCNO>
	<brief_summary>This study Phase I , open-label , single dose , mass balance study cohort 6 healthy adult male subject . The study consist : Screening evaluation , treatment phase , follow-up evaluation . In treatment phase , overnight fast least 10 hour , subject receive single oral suspension dose GSK2248761 200mg contain [ 14C ] - GSK2248761 . Following dosing , serial whole blood , plasma , urine , fecal sample collect . Subjects require remain unit radiocarbon excrete fall less equal 1 % administer dose two consecutive 24-hour collection urine feces , whichever occur first . Safety assess vital sign , 12-lead electrocardiogram ( ECG ) , clinical laboratory test , AE monitoring , physical examination indicate .</brief_summary>
	<brief_title>A Study Investigate Recovery , Excretion , Pharmacokinetics 14C-GSK2248761 Administered Oral Suspension Healthy Adult Subjects</brief_title>
	<detailed_description>ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male subject 30 55 year age . Male subject must agree use one contraception method list protocol . This criterion must follow time first dose study medication 84 day dose study medication . Male subject also must refrain donation sperm time well . Body weight great equal 50 kg body mass index ( BMI ) within range 18.531.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . Available complete study ( minimum 7 maximum 11 night 's confinement clinical research unit ) . A history regular bowel movement ( average one bowel movement per day ) . AST , ALT , alkaline phosphatase bilirubin great equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A single repeat allow eligibility determination . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . History sensitivity study medication , component thereof , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Use prescription nonprescription drug , include antacid , vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . If heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . History regular alcohol consumption within 6 month study Has history regular use tobacco nicotinecontaining product within 3 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . Subjects received total body radiation dose great 5.0 mSv ( upper limit WHO category II ) exposure significant radiation ( e.g . serial xray CT scan , barium meal etc ) 12 month prior study . Any previous radiolabeled study drug must receive 6 month prior checkin . Also total exposure current study previous study must within recommend level consider safe 5 Rems whole body annual exposure , per United States ( US ) Code Federal Regulations ( CFR ) 21 CFR 361.1 . Any condition could interfere accurate assessment recovery radiocarbon [ 14C ] . Unwillingness inability follow procedure outline protocol . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 45100 bpm . A single repeat allow determine eligibility . An abnormal ECG specify protocol ( single repeat allow eligibility determination ) .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>